Back

Cognition in AD treatment

Official Title

CoMTAD: Cognitive Monitoring during Treatment for Alzheimer disease

Study Details

The purpose of the study is to evaluate ultra-brief cognitive tests for monitoring adverse symptoms as part of the treatment for Alzheimer disease (AD).

Principal Investigator

Dr. Andrew Aschenbrenner

IRB Number

202311186

Eligibility

Participants must have been prescribed an AD treatment by a practicing physician.

Compensation is provided (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back